ID

33349

Description

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00788333

Lien

https://clinicaltrials.gov/show/NCT00788333

Mots-clés

  1. 06/12/2018 06/12/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

6 décembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00788333

Eligibility Breast Cancer NCT00788333

Criteria
Description

Criteria

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects with locally advanced or metastatic her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. prior treatment with other her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab dm-1 etc.) is allowed
Description

HER2-positive carcinoma of breast Advanced Locally | HER2-positive carcinoma of breast metastatic | Tuzumab Regimen Quantity failed | Pharmaceutical Preparations HER2 Targeted | lapatinib | pertuzumab | Trastuzumab-DM1

Type de données

boolean

Alias
UMLS CUI [1,1]
C1960398
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [2,1]
C1960398
UMLS CUI [2,2]
C1522484
UMLS CUI [3,1]
C0728747
UMLS CUI [3,2]
C0040808
UMLS CUI [3,3]
C1265611
UMLS CUI [3,4]
C0231175
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0069515
UMLS CUI [4,3]
C1521840
UMLS CUI [5]
C1506770
UMLS CUI [6]
C1328025
UMLS CUI [7]
C2935436
histologic or cytologic diagnosis of her-2-positive breast cancer
Description

HER2-positive carcinoma of breast

Type de données

boolean

Alias
UMLS CUI [1]
C1960398
ecog status 0 - 1
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
symptomatic brain metastasis
Description

Metastatic malignant neoplasm to brain Symptomatic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231220
any condition requiring chronic use of steroids
Description

Condition Requirement Steroids chronic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0038317
UMLS CUI [1,4]
C0205191
any disorder with dysregulation of glucose homeostasis (history of type 1 or 2 diabetes mellitus or prediabetic symptoms
Description

Abnormal glucose homeostasis | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Symptoms Prediabetic

Type de données

boolean

Alias
UMLS CUI [1]
C4023598
UMLS CUI [2]
C0011854
UMLS CUI [3]
C0011860
UMLS CUI [4,1]
C1457887
UMLS CUI [4,2]
C0362046
history of glucose intolerance
Description

Glucose intolerance

Type de données

boolean

Alias
UMLS CUI [1]
C0271650
women of child-bearing potential unwilling or unable to use acceptable contraception methods
Description

Childbearing Potential Contraceptive methods Unwilling | Childbearing Potential Contraceptive methods Unable

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C1299582

Similar models

Eligibility Breast Cancer NCT00788333

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
HER2-positive carcinoma of breast Advanced Locally | HER2-positive carcinoma of breast metastatic | Tuzumab Regimen Quantity failed | Pharmaceutical Preparations HER2 Targeted | lapatinib | pertuzumab | Trastuzumab-DM1
Item
subjects with locally advanced or metastatic her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. prior treatment with other her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab dm-1 etc.) is allowed
boolean
C1960398 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C1960398 (UMLS CUI [2,1])
C1522484 (UMLS CUI [2,2])
C0728747 (UMLS CUI [3,1])
C0040808 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0231175 (UMLS CUI [3,4])
C0013227 (UMLS CUI [4,1])
C0069515 (UMLS CUI [4,2])
C1521840 (UMLS CUI [4,3])
C1506770 (UMLS CUI [5])
C1328025 (UMLS CUI [6])
C2935436 (UMLS CUI [7])
HER2-positive carcinoma of breast
Item
histologic or cytologic diagnosis of her-2-positive breast cancer
boolean
C1960398 (UMLS CUI [1])
ECOG performance status
Item
ecog status 0 - 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain Symptomatic
Item
symptomatic brain metastasis
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Condition Requirement Steroids chronic
Item
any condition requiring chronic use of steroids
boolean
C0348080 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0205191 (UMLS CUI [1,4])
Abnormal glucose homeostasis | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent | Symptoms Prediabetic
Item
any disorder with dysregulation of glucose homeostasis (history of type 1 or 2 diabetes mellitus or prediabetic symptoms
boolean
C4023598 (UMLS CUI [1])
C0011854 (UMLS CUI [2])
C0011860 (UMLS CUI [3])
C1457887 (UMLS CUI [4,1])
C0362046 (UMLS CUI [4,2])
Glucose intolerance
Item
history of glucose intolerance
boolean
C0271650 (UMLS CUI [1])
Childbearing Potential Contraceptive methods Unwilling | Childbearing Potential Contraceptive methods Unable
Item
women of child-bearing potential unwilling or unable to use acceptable contraception methods
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial